Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
62
UTHR Quote, Financials, Valuation and Earnings
Last price:
$517.05
Seasonality move
:
5.61%
Day range:
$503.69 - $518.61
52-week range:
$266.98 - $518.61
Dividend yield:
0%
P/E ratio:
19.60x
P/S ratio:
7.97x
P/B ratio:
3.38x
Volume:
1.7M
Avg. volume:
485K
1-year change:
43.58%
Market cap:
$22.3B
Revenue:
$2.9B
EPS (TTM):
$26.39
Analysts' Opinion
-
Consensus RatingUnited Therapeutics Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $518.25, United Therapeutics Corp. has an estimated upside of 0.22% from its current price of $517.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $423.00 representing 18.2% downside risk from its current price of $517.13.
Fair Value
-
According to the consensus of 13 analysts, United Therapeutics Corp. has 0.22% upside to fair value with a price target of $518.25 per share.
UTHR vs. S&P 500
-
Over the past 5 trading days, United Therapeutics Corp. has overperformed the S&P 500 by 4.58% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
United Therapeutics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
United Therapeutics Corp. has grown year-over-year revenues for 20 quarters straight. In the most recent quarter United Therapeutics Corp. reported revenues of $799.5M.
Earnings Growth
-
United Therapeutics Corp. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter United Therapeutics Corp. reported earnings per share of $7.16.
Enterprise value:
19.5B
EV / Invested capital:
--
Price / LTM sales:
7.97x
EV / EBIT:
12.86x
EV / Revenue:
6.23x
PEG ratio (5yr expected):
1.23x
EV / Free cash flow:
17.47x
Price / Operating cash flow:
22.34x
Enterprise value / EBITDA:
12.20x
Gross Profit (TTM):
$2.8B
Return On Assets:
16.93%
Net Income Margin (TTM):
40.65%
Return On Equity:
19.2%
Return On Invested Capital:
18.69%
Operating Margin:
48.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.8B | $3.1B | $748.9M | $799.5M | |
| Gross Profit | $2B | $2.5B | $2.8B | $665.8M | $698.6M | |
| Operating Income | $1.1B | $1.3B | $1.5B | $343.1M | $389.3M | |
| EBITDA | $1.2B | $1.3B | $1.6B | $362.2M | $411.2M | |
| Diluted EPS | $18.15 | $22.77 | $26.39 | $6.39 | $7.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.4B | $3.1B | $3.5B | $4B | $3.5B | |
| Total Assets | $5B | $5.8B | $7B | $7.1B | $7.4B | |
| Current Liabilities | $320M | $315.9M | $744.1M | $873.4M | $546.3M | |
| Total Liabilities | $1.2B | $1.2B | $1.3B | $1B | $760.9M | |
| Total Equity | $3.8B | $4.6B | $5.7B | $6.1B | $6.6B | |
| Total Debt | $800M | $800M | $800M | $400M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $945.3M | $1.1B | $1.6B | $374.5M | $562.1M | |
| Cash From Investing | -$951M | $582.5M | -$446.9M | -$114.9M | $140.9M | |
| Cash From Financing | $146.6M | -$1.3B | -$1.3B | -$61.4M | -$956M | |
| Free Cash Flow | $754.1M | $898.1M | $1.1B | $298M | $346.1M | |
UTHR
Sector
Market Cap
$22.3B
$27.9M
Price % of 52-Week High
99.72%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
5.51%
-1.49%
1-Year Price Total Return
43.58%
-16.66%
Beta (5-Year)
0.861
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$500.34
200-day SMA
Buy
Level
$358.18
Bollinger Bands (100)
Buy
Level
349.87 - 481.55
Chaikin Money Flow
Buy
Level
1.8M
20-day SMA
Buy
Level
$488.96
Relative Strength Index (RSI14)
Buy
Level
73.13
ADX Line
Buy
Level
18.82
Williams %R
Sell
Level
-3.0528
50-day SMA
Buy
Level
$462.66
MACD (12, 26)
Buy
Level
96.31
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
1.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.4073)
Buy
CA Score
(Annual)
Level (2.1364)
Buy
Beneish M-Score
(Annual)
Level (-2.3521)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-6.3954)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Stock Forecast FAQ
In the current month, UTHR has received 8 Buy ratings 5 Hold ratings, and 0 Sell ratings. The UTHR average analyst price target in the past 3 months is $518.25.
-
Where Will United Therapeutics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that United Therapeutics Corp. share price will rise to $518.25 per share over the next 12 months.
-
What Do Analysts Say About United Therapeutics Corp.?
Analysts are divided on their view about United Therapeutics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that United Therapeutics Corp. is a Sell and believe this share price will drop from its current level to $423.00.
-
What Is United Therapeutics Corp.'s Price Target?
The price target for United Therapeutics Corp. over the next 1-year time period is forecast to be $518.25 according to 13 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is UTHR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for United Therapeutics Corp. is a Buy. 8 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UTHR?
You can purchase shares of United Therapeutics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase United Therapeutics Corp. shares.
-
What Is The United Therapeutics Corp. Share Price Today?
United Therapeutics Corp. was last trading at $517.05 per share. This represents the most recent stock quote for United Therapeutics Corp.. Yesterday, United Therapeutics Corp. closed at $517.13 per share.
-
How To Buy United Therapeutics Corp. Stock Online?
In order to purchase United Therapeutics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get UTHR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UTHR
Sector
P/E ratio
19.60x
23.85x
PEG ratio
1.23x
-0.01x
P/B ratio
3.38x
1.81x
Price / LTM sales
7.97x
1.58x
Growth Metrics
UTHR
Sector
Revenue growth
6.76%
4.62%
Earnings growth
12.12%
10.5%
Revenue (5-year growth)
14.71%
6.5%
Earnings forecast
$7.42
-$0.21
Profitability
UTHR
Sector
Profitability FY 2024
$2.6B
$3.6M
Return on invested capital
18.69%
-31.87%
Return on assets
16.93%
-28.18%
Return on equity
19.2%
-37.63%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Jan
28
Balance Sheet
UTHR
Sector
Total cash
$2.8B
$26.4M
Short term investments
$1.6B
$25.7M
Total assets
$7.4B
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
